New phase III data shows investigational antibody cocktail casirivimab and imdevimab reduced hospitalisation or death by 70% in non-hospitalised patients with COVID-19

Regeneron, Press Release, Mar 2021
Early treatmentRCT · 2,696 patients · USA
Casirivimab/i.. for COVID-19
Regeneron Press Release · March 2021
Lower death/hosp. and faster recovery
p < 0.0001 (death/hosp.) and p = 0.0001 (recovery)

Casirivimab/imdevimab for COVID-19

17th treatment shown to reduce risk in March 2021, now with p = 0.000095 from 34 studies, recognized in 52 countries. Efficacy is variant dependent.

No treatment is 100% effective.
Protocols combine treatments.

Press release for new phase III data showing lower hospitalization/mortality, and faster symptom resolution among the subset of patients with at least one risk factor.
Some variants may escape antibodies1.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants2-8.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments9. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
OutcomeImprovementEffect · pTreatmentControl
risk of death/hospitalization 71.3% lower · RR 0.29 · p < 0.001*** 71.3% lowerRR 0.29p < 0.001*** 18 of 1,355 (1.3%) 62 of 1,341 (4.6%) treatment 18 of 1,355 (1.3%), control 62 of 1,341 (4.6%)2,400mg IV, ≥1 risk factorNNT 30
risk of death/hospitalization 70.4% lower · RR 0.30 · p = 0.003** 70.4% lowerRR 0.30p = 0.003** 7 of 736 (1.0%) 24 of 748 (3.2%) treatment 7 of 736 (1.0%), control 24 of 748 (3.2%)1,200mg IV, ≥1 risk factorNNT 44
recovery time 28.6% lower · relative time 0.71 · p < 0.0001*** 28.6% lowerrelative time 0.71p < 0.0001*** 1,355 1,341 treatment 1,355, control 1,3412,400mg IV, ≥1 risk factor
recovery time 28.6% lower · relative time 0.71 · p < 0.0001*** 28.6% lowerrelative time 0.71p < 0.0001*** 736 748 treatment 736, control 7481,200mg IV, ≥1 risk factor

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates. ** p < 0.01   *** p < 0.001

Regeneron et al., 23 Mar 2021, Randomized Controlled Trial, USA, preprint, 1 author.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 USA Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia USA favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%